Loading...
01/11 11:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a challenging environment with decreased revenues, competitive pressures, and regulatory issues. The lack of reimbursement coverage for TearCare and declining MIGS utilization are concerning. Despite a slight decrease in net loss, the company faces tariff impacts and lacks a share repurchase program. The Q&A section highlights management's evasive responses on key issues, adding to uncertainty. Overall, the negative factors outweigh any positives, leading to a negative sentiment rating.
Total Revenue $17.5 million, a decrease of 9% year-over-year due to market dynamics in the MIGS sector.
Surgical Glaucoma Revenue $17.1 million, a decrease of 6% year-over-year, primarily due to a 10% decrease in account utilization linked to new Medicare LCD restrictions.
Dry Eye Revenue $400,000, a decrease from $1 million year-over-year, primarily due to fewer SmartLids sales following a price increase.
Gross Margin 86%, flat year-over-year, with no impact from tariffs in Q1 2025 as inventory was purchased prior to tariff implementation.
Total Operating Expenses $29 million, a decrease of 7% year-over-year, primarily due to lower legal fees.
Adjusted Operating Expenses $24.7 million, a decrease of 7% year-over-year, reflecting ongoing fiscal discipline.
Net Loss $14.2 million, or $0.28 per share, compared to a net loss of $16.3 million, or $0.33 per share, in Q1 2024.
Cash and Cash Equivalents $108 million, with $40 million of debt.
Cash Used $11.6 million in Q1 2025, including annual bonus payments.
New Product Launch: Launched next-generation OmniEdge, designed to treat primary open-angle glaucoma patients with improved viscodilation and safety.
Market Expansion: Evaluating additional manufacturing locations outside of China to reduce tariff costs, with a new manufacturing line expected in 9-12 months.
Market Positioning: Focused on building commercial momentum in MIGS through customer education and engagement, and establishing equitable reimbursement for TearCare.
Operational Efficiency: Reduced adjusted operating expenses guidance for full year 2025 to $101 million - $105 million, reflecting a focus on fiscal discipline.
Strategic Shift: Adapting commercial approach in response to new Medicare coverage restrictions for MIGS procedures.
Tariff Costs: Material tariff increases on goods imported from China are expected to increase the cost of goods sold starting in Q2 2025. The surgical glaucoma segment's unmitigated tariff exposure could increase costs by $3.5 million to $4.5 million for full year 2025.
Manufacturing Expansion: The company is evaluating additional manufacturing locations outside of China to mitigate tariff costs, with new lines expected to be operational in 9-12 months.
Medicare Coverage Restrictions: New Medicare coverage restrictions limit coverage to only one MIGS procedure performed with cataract surgery, impacting account utilization and revenue.
Dry Eye Revenue: Dry eye revenue is expected to remain modest until reimbursement coverage decisions for TearCare are made, with current revenue at $400,000, down from $1 million in the prior year.
Market Competition: The company faces competitive pressures in the MIGS market, particularly with the introduction of new products and evolving surgeon preferences.
Regulatory Issues: The company is awaiting reimbursement coverage decisions for TearCare, which are critical for future revenue growth.
Key Strategic Initiatives: Focus on building commercial momentum in MIGS through customer education and engagement, establishing equitable reimbursement for TearCare, publishing new clinical and economic data, supporting adoption of interventional technologies, and progressing product pipeline including next-generation Omni release.
Manufacturing Expansion: Evaluating additional manufacturing locations outside of China to lower tariff costs, with a new manufacturing line expected to be operational in 9-12 months.
Surgeon Engagement: Engaging accounts around reimbursement clarity and enhancing competitive counter-selling to optimize commercial approach.
Product Pipeline: Recent launch of next-generation OmniEdge to address diverse patient needs in the MIGS market.
Market Access Initiatives: Advancing market access initiatives for TearCare to establish equitable reimbursement.
Revenue Guidance: Reaffirming revenue guidance for full year 2025 of approximately $70 million to $75 million, considering the impact of new Medicare LCD.
Dry Eye Revenue Outlook: Expecting approximately $1 million in revenue for the dry eye segment for full year 2025, pending reimbursement decisions.
Adjusted Operating Expenses Guidance: Revised adjusted operating expenses guidance for full year 2025 to $101 million to $105 million, reflecting a 0% to 4% increase compared to 2024.
Tariff Impact: Unmitigated tariff exposure expected to increase surgical glaucoma segment's cost of goods sold by $3.5 million to $4.5 million for full year 2025.
Share Repurchase Program: None
The company has shown improved financial performance with reduced operating expenses and net loss. Raised revenue guidance and strategic focus on TearCare's growth potential indicate optimism. Despite some uncertainties in the Q&A, the engagement and expansion plans for TearCare and the MIGS market suggest positive sentiment. The market's reaction is likely to be positive, considering the strategic initiatives and financial improvements.
The earnings call reveals mixed signals: the company reports declining dry eye revenue and gross margins, alongside a net loss. However, they also demonstrate strong performance in the Surgical Glaucoma segment, reduced operating expenses, and positive cash flow. The Q&A highlights confidence in reimbursement for TearCare and market share gains in MIGS, but uncertainties in reimbursement timing and competitive dynamics persist. These factors, coupled with stable guidance, suggest a neutral stock price movement over the next two weeks.
The earnings call reveals a challenging environment with decreased revenues, competitive pressures, and regulatory issues. The lack of reimbursement coverage for TearCare and declining MIGS utilization are concerning. Despite a slight decrease in net loss, the company faces tariff impacts and lacks a share repurchase program. The Q&A section highlights management's evasive responses on key issues, adding to uncertainty. Overall, the negative factors outweigh any positives, leading to a negative sentiment rating.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
